Panacea Biotec Share Price
383.20-5.85 (-1.50%)
-9.58% past 1 Year
Panacea Biotec Limited is one of India’s leading research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. The company
Corporate filings & documents
Announcements
Please find enclosed newspaper copies of the public notice requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.
2 weeks agoPlease find enclosed newspaper copies of the public notice requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.
2 weeks agoPlease find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026 published on 14.08.2026.
2 weeks agoPlease find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026 published on 14.08.2026.
2 weeks agoPlease find attached Unaudited Financial Results for quarter ended June 30 2026.
3 weeks agoPlease find attached Unaudited Financial Results for quarter ended June 30 2026.
3 weeks agoPlease find attached Outcome of Board Meeting held on August 13 2026.
3 weeks agoPlease find attached Outcome of Board Meeting held on August 13 2026.
3 weeks agoPlease find attached newspaper copies regarding notice intimating the investors about the opening of Special Window for transfer and dematerialisation of physical shares.
3 weeks agoPlease find attached newspaper copies regarding notice intimating the investors about the opening of Special Window for transfer and dematerialisation of physical shares.
3 weeks agoPanacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2026.The trading window of the Company shall remain closed for all Designated Persons (including their Immediate Relatives) of the Company from July 01 2026 till August 15 2026.
3 weeks agoPanacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2026.The trading window of the Company shall remain closed for all Designated Persons (including their Immediate Relatives) of the Company from July 01 2026 till August 15 2026.
3 weeks agoPlease find attached details of shares dematerialised during July 2026.
1 month agoPlease find attached details of shares dematerialised during July 2026.
1 month agoWe are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million (~Rs.78.24 Crore) in Calendar Year 2028.
1 month agoWe are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million (~Rs.78.24 Crore) in Calendar Year 2028.
1 month agoThe Companys wholly owned subsidiary Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23 2026 from the office of the Assistant Commissioner Goods and Services Tax Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules 2017 alleging total tax liability of Rs.4.06 Crore including interest tax and penalty on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23.The requisite disclosure is attached herewith.
1 month agoThe Companys wholly owned subsidiary Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23 2026 from the office of the Assistant Commissioner Goods and Services Tax Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules 2017 alleging total tax liability of Rs.4.06 Crore including interest tax and penalty on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23.The requisite disclosure is attached herewith.
1 month agoWe would like to inform you that the Company has on July 16 2026 filed appeal before the Honble High Court of Punjab and Haryana Chandigarh against the remaining 4th award. The requisite disclosure is attached herewith.
1 month agoWe would like to inform you that the Company has on July 16 2026 filed appeal before the Honble High Court of Punjab and Haryana Chandigarh against the remaining 4th award. The requisite disclosure is attached herewith.
1 month agoThe Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Jain HUF
1 month agoThe Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Jain HUF
1 month agoPlease find attached disclosure which is self explanatory
1 month agoPlease find attached disclosure which is self explanatory
1 month agoPlease find attached certificate dated July 01 2026 issued by Skyline Financial Services Pvt. Ltd. RTA under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026.
1 month agoPlease find attached certificate dated July 01 2026 issued by Skyline Financial Services Pvt. Ltd. RTA under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026.
1 month agoWe would like to inform that no share has been dematerialised during June 2026. A copy of the certificate obtained from the Companys RTA viz. Skyline Financial Services Pvt. Ltd. regarding shares dematerialised as on June 30 2026 is enclosed herewith.
1 month agoWe would like to inform that no share has been dematerialised during June 2026. A copy of the certificate obtained from the Companys RTA viz. Skyline Financial Services Pvt. Ltd. regarding shares dematerialised as on June 30 2026 is enclosed herewith.
1 month agoWe would like to inform you that the trading window of the Company shall remain closed from July 01 2026 till completion of 48 hours from the announcement of the Unaudited financial results for the quarter ending June 30 2026 to the Stock Exchanges.
2 months agoWe would like to inform you that the trading window of the Company shall remain closed from July 01 2026 till completion of 48 hours from the announcement of the Unaudited financial results for the quarter ending June 30 2026 to the Stock Exchanges.
2 months agoThe Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dr Rajesh Jain
2 months agoThe Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dr Rajesh Jain
2 months agoPlease find attached newspaper copies regarding notice intimating the investors about the opening of a special window for transfer and dematerialisation of physical shares.
2 months agoPlease find attached newspaper copies regarding notice intimating the investors about the opening of a special window for transfer and dematerialisation of physical shares.
2 months agoPanacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate its broader global use. A copy of the Press Release is attached herewith.
2 months agoPanacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate its broader global use. A copy of the Press Release is attached herewith.
2 months agoThe Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Jain HUF
3 months agoThe Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Jain HUF
3 months agoPlease find attached details of shares dematerialised during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018
3 months agoPlease find attached details of shares dematerialised during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018
3 months agoPlease find attached copies of newspaper publication of Audited Financial Results for the quarter and financial year ended March 31 2026.
3 months agoPlease find attached results
3 months agoWe would like to inform you that the Board of Directors has at its meeting held today i.e. 30.05.2026 approved the appointment of Mr. Rajinder Singh Manku as an additional director in the capacity of non-executive independent director for a term of 5 years w.e.f. July 01 2026.
3 months agoWe would like to inform you that the Board of Directors has at its meeting held today i.e. Saturday May 30 2026 inter-alia considered and approved:1. the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31 2026. The same was also reviewed by the Audit Committee in its meeting held on May 29 2026. A copy of the said statements of financial results along with the Auditors Report.2. Passing over of dividend on the equity as well as preference shares of the Company for the financial year 2025-26 on account of losses during the year.3. The appointment of Mr. Rajinder Singh Manku (DIN: 09706881) as an additional director in the capacity of non-executive independent director not liable to retire by rotation for a term of 5 consecutive years w.e.f. July 01 2026.
3 months agoWe would like to inform you that the Board of Directors of the Companys material wholly owned subsidiary Panacea Biotec Pharma Ltd. has in its meeting held today i.e. 29.05.2026 inter-alia approved the appointment / re-appointment of directors.Intimation with requisite details is enclosed herewith.
3 months agoPlease find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries Practicing Company Secretaries for the financial year ended March 31 2026.
3 months agoPlease find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries Practicing Company Secretaries for the financial year ended March 31 2026.
3 months agoThe Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026
3 months agoThe Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026
3 months agoPanacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve Standalone and Consolidated Audited Financial Results for Quarter and Financial Year ended March 31 2026.The Board may also consider the matter relating to recommendation / passing over of dividend on equity as well as preference shares for the said Financial Year
3 months agoAnnual reports
Concalls & investor presentations
Jun 2021
ConcallPresentation
Corporate Actions
Date
Type
Details
2011-09-19
Dividend
0.75
2010-09-16
Dividend
0.25
Company details
Registered office
Ambala - Chandigarh Highway NULL NULL Lalru Punjab PIN: 140501 Tel No: 01762- 505900 Fax No: 01762- 505909 / 505906 Email: [email protected] Internet: www.panaceabiotec.com
Registrars
D-153/A, 1st Floor,Okhla Industrial Area, Phase - I, New Delhi - 110020 D-153/A, 1st Floor Okhla Industrial Area Phase - I PIN: Tel No: 91-011-26812682/84 Fax No: 91-11-26292681 Email: [email protected]
Management
Ankit Jain, Company Secretary and Compliance Officer
Rajesh Jain, Chairman & Managing Director
Rajesh Jain, Chairman & Managing Director
Sandeep Jain, Joint Managing Director
Ankesh Jain, Whole Time Director
Harshet Jain, Whole Time Director
Sanjay Trehan, Executive Director - Technical & Compliances
Ambika Sharma, Non Executive Independent Director
Krishan Kumar Jalan, Non Executive Independent Director
Rajesh Jain, Non Executive Independent Director
Rajender Pal Singh, Non Executive Independent Director
Venkatesh Sarvasiddhi, Non Executive Independent Director
Details
BSE 531349
NSE PANACEABIO
ISIN INE922B01023